中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 12
Dec.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(12): 2761-2766

Effectiveness and safety of programmed cell death-1 inhibitor in the treatment of advanced non-HBV non-HCV-related hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.12.015
  • a.

    Department of Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China

  • b.

    Department of General Surgery, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China

  • c.

    Department of Gastroenterology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China

Research funding:

Jiangsu Province High-level Health Talents "Six Ones Project" Category A Project (LGY2020006)

More Information
  • Corresponding author: HAN Zhengxiang, cnhzxyq@163.com (ORCID: 0000-0002-1199-8983)
  • Received Date: 2022-06-11
  • Accepted Date: 2022-07-12
  • Published Date: 2022-12-20
    Abstract
  •   Objective  To investigate the clinical effectiveness and adverse events of domestic programmed cell death -1 (PD-1) inhibitor in the treatment of advanced non-HBV non-HCV-related hepatocellular carcinoma (NBNC-HCC).  Methods  A totals of 31 patients with advanced NBNC-HCC who received domestic PD-1 inhibitor in the Affiliated Hospital of Xuzhou Medical University from June 2019 to February 2022 were retrospectively enrolled and their clinicopathological data were retrieved from their medical records and analyzed, i.e., the time to disease progression (TTP), disease control rate (DCR), objective response rate (ORR), and adverse events were recorded and statistically analyzed. The Kaplan-Meier method was used for survival analysis.  Results  Among these 31 patients, only one achieved the complete response and four achieved the partial response, and six had the stable disease, but 20 showed a disease progression, resulting in an ORR of 16.1% and a (DCR of 35.5%. The median TTP was 7.2 months [95% confidence interval: 6.4-8.0) months]. The incidence of adverse events was 61.30% and the common adverse events were skin rash (29.03%) and hypertension (22.58%). However, there was no grade 4 adverse reactions or related death in these patients.  Conclusion  Advanced NBNC-HCC patients had a relative weak response to the PD-1 inhibitor although the adverse events were controllable. Future multi-center prospective clinical trials are needed to validate the data.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
    [2]
    NENU I, BREABAN I, PASCALAU S, et al. The future is now: beyond first line systemic therapy in hepatocellular carcinoma[J]. Transl Cancer Res, 2019, 8(Suppl 3): S261-S274. DOI: 10.21037/tcr.2018.11.23.
    [3]
    XUE X, LIAO W, XING Y. Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma[J]. Infect Agent Cancer, 2020, 15: 11. DOI: 10.1186/s13027-020-0273-2.
    [4]
    BSISU I, RMILAH AA. Global elimination of chronic hepatitis[J]. N Engl J Med, 2019, 381(6): 589. DOI: 10.1056/NEJMc1908197.
    [5]
    SEKO Y, YAMAGUCHI K, ITOH Y. The genetic backgrounds in nonalcoholic fatty liver disease[J]. Clin J Gastroenterol, 2018, 11(2): 97-102. DOI: 10.1007/s12328-018-0841-9.
    [6]
    MALUCCIO M, COVEY A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma[J]. CA Cancer J Clin, 2012, 62(6): 394-399. DOI: 10.3322/caac.21161.
    [7]
    CHUNG SY, KIM KJ, SEONG J. Biomarkers for locally advanced hepatocellular carcinoma patients treated with liver-directed combined radiotherapy[J]. Liver Cancer, 2022, 11(3): 247-255. DOI: 10.1159/000522000.
    [8]
    FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
    [9]
    EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
    [10]
    ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/S1470-2045(18)30351-6.
    [11]
    PFISTER D, NÚÑEZ NG, PINYOL R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC[J]. Nature, 2021, 592(7854): 450-456. DOI: 10.1038/s41586-021-03362-0.
    [12]
    JI F, NGUYEN MH. Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy[J]. Lancet Oncol, 2022, 23(8): 962-963. DOI: 10.1016/S1470-2045(22)00383-7.
    [13]
    KELLEY RK, RIMASSA L, CHENG AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2022, 23(8): 995-1008. DOI: 10.1016/S1470-2045(22)00326-6.
    [14]
    LENCIONI R, LLOVET JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60. DOI: 10.1055/s-0030-1247132.
    [15]
    European Association for the Study of the Liver. Corrigendum to "EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma"[J Hepatol 69 (2018) 182-236][J]. J Hepatol, 2019, 70(4): 817. DOI: 10.1016/j.jhep.2019.01.020.
    [16]
    KUDO M, MATILLA A, SANTORO A, et al. CheckMate 040 cohort 5: A phase Ⅰ/Ⅱ study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis[J]. J Hepatol, 2021, 75(3): 600-609. DOI: 10.1016/j.jhep.2021.04.047.
    [17]
    WANG F, QIN S, SUN X, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial[J]. J Hematol Oncol, 2020, 13(1): 47. DOI: 10.1186/s13045-020-00886-2.
    [18]
    ONZI G, MORETTI F, BALBINOT S S, et al. Hepatocellular carcinoma in non-alcoholic fatty liver disease with and without cirrhosis[J]. Hepato Res, 2019, 5: 7. DOI: 10.20517/2394-5079.2018.114.
    [19]
    DEGASPERI E, COLOMBO M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease[J]. Lancet Gastroenterol Hepatol, 2016, 1(2): 156-164. DOI: 10.1016/S2468-1253(16)30018-8.
    [20]
    XU W, ZHANG X, WU JL, et al. O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress[J]. J Hepatol, 2017, 67(2): 310-320. DOI: 10.1016/j.jhep.2017.03.017.
    [21]
    SHEN ZQ, CHEN YF, CHEN JR, et al. CISD2 haploinsufficiency disrupts calcium homeostasis, causes nonalcoholic fatty liver disease, and promotes hepatocellular carcinoma[J]. Cell Rep, 2017, 21(8): 2198-2211. DOI: 10.1016/j.celrep.2017.10.099.
    [22]
    SCHUSTER S, CABRERA D, ARRESE M, et al. Triggering and resolution of inflammation in NASH[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(6): 349-364. DOI: 10.1038/s41575-018-0009-6.
    [23]
    BOLAND P, WU J. Systemic therapy for hepatocellular carcinoma: beyond sorafenib[J]. Chin Clin Oncol, 2018, 7(5): 50. DOI: 10.21037/cco.2018.10.10.
    [24]
    BENSON AB, D'ANGELICA MI, ABBOTT DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5): 541-565. DOI: 10.6004/jnccn.2021.0022.
    [25]
    General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [26]
    RODERBURG C, WREE A, DEMIR M, et al. The role of the innate immune system in the development and treatment of hepatocellular carcinoma[J]. Hepat Oncol, 2020, 7(1): HEP17. DOI: 10.2217/hep-2019-0007.
    [27]
    QIN S, REN Z, MENG Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-580. DOI: 10.1016/S1470-2045(20)30011-5.
    [28]
    CHEN J, HU X, LI Q, et al. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients[J]. Ann Transl Med, 2020, 8(18): 1187. DOI: 10.21037/atm-20-6063.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1464) PDF downloads(57) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return